[HTML][HTML] Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized …
DM Paulson, DT Kennedy, RA Donovick… - The Journal of …, 2005 - Elsevier
Alvimopan has been shown to reverse the inhibitory effect of opioids on gastrointestinal
transit without affecting analgesia. We evaluated oral alvimopan, 0.5 or 1 mg, versus
placebo, once daily for 21 days, in 168 patients with opioid-induced bowel dysfunction
(OBD) who were receiving chronic opioid therapy (minimum, 1 month) for nonmalignant pain
(n= 148) or opioid dependence (n= 20). The primary outcome was the proportion of patients
having at least one bowel movement (BM) within 8 hours of study drug on each day during …
transit without affecting analgesia. We evaluated oral alvimopan, 0.5 or 1 mg, versus
placebo, once daily for 21 days, in 168 patients with opioid-induced bowel dysfunction
(OBD) who were receiving chronic opioid therapy (minimum, 1 month) for nonmalignant pain
(n= 148) or opioid dependence (n= 20). The primary outcome was the proportion of patients
having at least one bowel movement (BM) within 8 hours of study drug on each day during …
